Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

MDX-1411

Alternative Names: mdx-1411, mdx1411, mdx 1411
Latest Update: 2013-05-14
Latest Update Note: Clinical Trial Update

Product Description

We are developing MDX-1411, a fully human antibody that targets the CD70 receptor, which is a member of the tumor necrosis factor family and expressed in a number of cancers, including renal cell cancer, and certain types of leukemia and lymphoma.

Mechanisms of Action: CD70 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Kidney Cancer|Renal Cell Carcinoma|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MDX1411-02

P1

Withdrawn

Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia

2012-12-01

MDX1411-01

P1

Completed

Kidney Cancer|Renal Cell Carcinoma

2010-06-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions